Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 15, 2020 08:00 ET | Source: Larimar Therapeutics, Inc.

Larimar Therapeutics Added to NASDAQ Biotechnology Index

BALA CYNWYD, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
December 08, 2020 07:30 ET | Source: Larimar Therapeutics, Inc.

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

- Preliminary data suggest that single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg - Company remains on track to report topline data from placebo-controlled single...
November 13, 2020 08:00 ET | Source: Larimar Therapeutics, Inc.

Larimar Therapeutics to Participate in Upcoming Investor Conferences

BALA CYNWYD, Pa., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
November 10, 2020 08:00 ET | Source: Larimar Therapeutics, Inc.

Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results

Phase 1 trials evaluating CTI-1601 as a treatment for Friedreich’s ataxia on track for topline data in 1H 2021 Received orphan drug designation for CTI-1601 from the European Commission Cash, cash...
October 13, 2020 08:00 ET | Source: Larimar Therapeutics, Inc.

Larimar Therapeutics Announces Formation of Scientific Advisory Board

BALA CYNWYD, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today...
September 21, 2020 09:58 ET | Source: Larimar Therapeutics, Inc.

Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

BALA CYNWYD, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
September 10, 2020 08:00 ET | Source: Larimar Therapeutics, Inc.

Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference

BALA CYNWYD, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
August 11, 2020 07:00 ET | Source: Larimar Therapeutics, Inc.

Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results

Merger between Chondrial Therapeutics and Zafgen completed and company began operating as Larimar TherapeuticsPhase 1 clinical trial of CTI-1601 for treatment of Friedreich’s ataxia restarts after...
August 04, 2020 08:00 ET | Source: Larimar Therapeutics, Inc.

Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference

BALA CYNWYD, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today...
July 28, 2020 08:00 ET | Source: Larimar Therapeutics, Inc.

Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia

BALA CYNWYD, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today...